Page 1 of 9

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13D


                   Under the Securities Exchange Act of 1934
                               (Amendment No. 1)1/
                                                -

                               CONMED Corporation
                        --------------------------------
                                (Name of Issuer)


                         Common Stock, $0.01 par value
                     --------------------------------------
                         (Title of Class of Securities)


                                    20741010
                                    --------
                                 (CUSIP Number)


                                  Zimmer, Inc.
                            727 North Detroit Street
                           Warsaw, Indiana 46580-0708
                                 (219) 267-6131
                     --------------------------------------
            (Name, Address and Telephone Number of Person Authorized
                     to Receive Notices and Communications)


                                 March 20, 1996
                            -----------------------
                         (Date of Event which Requires
                           Filing of this Statement)


If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  which  is the  subject  of  this  Statement  because  of  Rule
13d-1(b)(3) or (4), check the following box: []

Check the following box if a fee is being paid with this Statement:[]. (A fee is
not required only if the reporting person:  (1) has a previous statement on file
reporting  beneficial  ownership  of more  than  five  percent  of the  class of
securities  described  in Item 1;  and (2) has  filed  no  amendment  subsequent
thereto reporting  beneficial  ownership of five percent or less of such class.)
(See Rule 13d-7.)

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934, as amended (the "Exchange  Act"), or otherwise  subject to the liabilities
of that section of the Exchange Act but shall be subject to all other provisions
of the Exchange Act.


- ----------
1. The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent   amendment   containing   information  which  would  alter
disclosures provided in a prior cover page.







                                                                    Page 2 of 9

                                  SCHEDULE 13D

- ---------------------------

  CUSIP No.  20741010

- ---------------------------

  1  NAME OF REPORTING PERSON
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

                    ZIMMER, INC.
                    I.R.S. Employer Identification Number 13-2695416
- --------------------------------------------------------------------------------

  2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                    (a) [ ]
                                                                         (b) [X]
- --------------------------------------------------------------------------------

  3  SEC USE ONLY

- --------------------------------------------------------------------------------

  4  SOURCE OF FUNDS

                    Not Applicable

- --------------------------------------------------------------------------------

  5  CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED                [ ]
     PURSUANT TO ITEMS 2(d) OR 2(e)
- --------------------------------------------------------------------------------

  6  CITIZENSHIP OR PLACE OF ORGANIZATION

                    Delaware
- --------------------------------------------------------------------------------

NUMBER OF           7       SOLE VOTING POWER
                            0
 SHARES             ------------------------------------------------------------
                    8       SHARED VOTING POWER
BENEFICIALLY                0
                    ------------------------------------------------------------
 OWNED BY           9       SOLE DISPOSITIVE POWER
                            0
 PERSON             ------------------------------------------------------------
                    10      SHARED DISPOSITIVE POWER
  WITH                      0
- --------------------------------------------------------------------------------

  11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                    0
- --------------------------------------------------------------------------------

  12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [ ]
- --------------------------------------------------------------------------------

  13 PERCENT OF CLASS REPRESENTED BY AMOUNT ON ROW (11)

                    0%
- --------------------------------------------------------------------------------

  14 TYPE OF REPORTING PERSON

                    CO
- --------------------------------------------------------------------------------






CUSIP No.  20741010                                                 Page 3 of 9






                        AMENDMENT NO. 1 TO SCHEDULE 13D
                        -------------------------------


                  This  statement  amends and restates the items set forth below
of the Schedule  13D of Zimmer,  Inc.  (the  "Company")  dated  February 6, 1996
relating to the common  stock(the  "Common  Stock") of CONMED  Corporation  (the
"Issuer").



Item 3.    Source and Amount of Funds or Other Consideration.
           --------------------------------------------------

                  Until March 20, 1996, the Company beneficially owned shares of
Common Stock pursuant to a Warrant to Purchase Common Stock,  dated as of August
31,  1989 (the  "Warrant"),  issued by the Issuer to the Company as a portion of
the  purchase  price paid by the Issuer to the  Company in  connection  with the
Issuer's acquisition of Aspen Laboratories, Inc., then a wholly-owned subsidiary
of the Company,  in August 1989. The number of shares of Common Stock covered by
the Warrant and the  purchase  price per share of Common Stock were each subject
to adjustment  from time to time pursuant to and in accordance with the terms of
the  Warrant.  The  number of shares of Common  Stock  issuable  to the  Company
pursuant  to the Warrant was 704,589  shares of Common  Stock  exercisable  at a
purchase  price of $4.2578 per share (as  adjusted  pursuant to the terms of the
Warrant),  as of March 20,  1996.  The Warrant was  exercised  by the Company on
March 20, 1996 with  respect to all of the shares of Common  Stock  beneficially
owned by the Company at a purchase price of $4.2578 per share in connection with
an  underwritten  public  offering by the Issuer of  3,350,000  shares of Common
Stock for cash  proceeds  payable to the Issuer (the  "Offering"),  plus 502,500
additional   shares  of  Common  Stock  sold  by  the  Issuer  pursuant  to  the
underwriters' over-allotment option.






CUSIP No.  20741010                                                 Page 4 of 9







Item 4.  Purpose of Transaction.
         -----------------------

                  On August 24, 1989,  the Company and the Issuer entered into a
Stock Purchase Agreement (the "Stock Purchase  Agreement") pursuant to which the
Issuer  purchased from the Company all of the issued and  outstanding  shares of
capital  stock of Aspen  Laboratories,  Inc.  Pursuant to the terms of the Stock
Purchase  Agreement,  the  purchase  price  paid by the  Issuer  to the  Company
consisted of both cash consideration and the Warrant.

                  On March  20,  1996,  in  connection  with the  Offering,  the
Company  exercised the Warrant at a purchase  price of $4.2578 per share for all
of the shares of Common Stock (the "Warrant Shares")  beneficially  owned by the
Company.  The Company also  exercised its  registration  rights  pursuant to the
terms of the  Warrant  and sold all of the shares of Common  Stock of the Issuer
beneficially held by the Company as part of the Offering.

Item 5.  Interest in Securities of the Issuer.
         -------------------------------------

                  To the best knowledge of the Company,  upon  completion of the
Offering,  the Issuer has  outstanding  14,852,605  shares of Common Stock. As a
result of the registration and sale of the Warrant Shares,  the Company does not
own  (beneficially,  of record or  otherwise)  any shares of Common Stock of the
Issuer.  Except as set forth in this Item 5 and on  Schedule A  attached  hereto
which is incorporated  herein by reference,  neither the Company,  Bristol-Myers
Squibb,  nor, to the best  knowledge  of the  Company,  any of their  respective
executive officers or directors owns any shares of Common Stock.





CUSIP No.  20741010                                                 Page 5 of 9





                  Except as set forth on  Schedule  A attached  hereto  which is
incorporated  herein by reference,  and other than the transactions with respect
to the Offering as described herein,  neither the Company,  Bristol-Myers Squibb
nor, to the best  knowledge of the Company,  any of their  respective  executive
officers or directors  has effected  any  transaction  in shares of Common Stock
during the past sixty (60) days.

                  The Issuer registered shares of its Common Stock in connection
with the  Offering.  Pursuant  to,  and in  accordance  with the terms  of,  the
Warrant,  the Company has exercised its registration  rights with respect to all
of the shares  covered by the  Warrant,  and has sold all such shares as part of
the Offering.  Upon  completion of the Offering,  on March 20, 1996, the Company
ceased to be a beneficial owner of securities of the Issuer.

Item 6.  Contracts, Arrangements, Understanding or Relationships With Respect to
         Securities of the Issuer.
         -----------------------------------------------------------------------

                  Each of the  Company,  Bristol-Myers  Squibb  and, to the best
knowledge of the Company,  their respective  executive officers and directors is
not a party to any  contracts,  arrangements,  understandings  or  relationships
(legal or  otherwise)  with any person  with  respect to any  securities  of the
Issuer.

Item 7.  Material to be Filed as Exhibits.
         ---------------------------------

                  Exhibit  3.  Registration  Statement  on Form  S-2 as filed by
                  CONMED Corporation with the Securities and Exchange Commission
                  in  connection  with the March 20,  1996  underwritten  public
                  offering  of  3,350,000  shares  of 





CUSIP No.  20741010                                                 Page 6 of 9





                  Common  Stock  of  CONMED  Corporation  for  cash   proceeds 
                  payable   to  the  CONMED Corporation (File No.  33-65287).2/
                                                                             -













                                                  

- ---------
2. Incorporated by reference.





CUSIP No.  20741010                                                 Page 7 of 9







                                   SIGNATURE
                                   ---------

                  After  reasonable  inquiry and to the best of my knowledge and
belief,  I certify  that the  information  set forth in this  Statement is true,
complete and correct.

Dated:  April 5, 1996

                                       ZIMMER, INC.

                                       By:/s/ Timothy M. Wendt
                                          --------------------
                                          Timothy M. Wendt
                                          Senior Vice President






CUSIP No.  20741010                                                 Page 8 of 9







                                   SCHEDULE A
                                   ----------

                          Shares of Common Stock Owned
                          ----------------------------

                                     None.




                     Transactions in Shares of Common Stock
                            during the Last 60 Days
                     --------------------------------------

                                     None.





CUSIP No.  20741010                                                 Page 9 of 9






                                 EXHIBIT INDEX
                                 -------------


Exhibit
Number            Document
- -------           --------

3                 Registration   Statement  on  Form  S-2  as  filed  by  CONMED
                  Corporation  with the  Securities  and Exchange  Commission in
                  connection  with  the  March  20,  1996  underwritten   public
                  offering  of  3,350,000  shares  of  Common  Stock  of  CONMED
                  Corporation   for  cash   proceeds   payable   to  the  CONMED
                  Corporation (File No. 33-65287).3/
                                                  -
- ---------
3. Incorporated by reference.